Cholesterol Screen denials in California external review

In the California DMHC record, independent physician reviewers decided 13 published external-review cases involving Cholesterol Screenand overturned the plan’s denial in 0%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
13
2011–2025
Overturned
0%
0 denials reversed

Conditions behind Cholesterol Screen denials

What insurers denied — and how those fights ended.
CategoryDecisionsOverturned
High Cholesterol3
0%
Typical time to a decision
17 days
Most land between 14 and 23 days

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for cardiac marker laboratory testing for the stated condition of family history of high cholesterol. The American College of Cardiology (ACC) as well as the American Heart Association (AHA) guidelines currently do not recommend routine performance of specialized tests in the context of assessing coronary risk including lipoprotein-associated phospholipase A2 (Lp-PLA2), sub-classifications of LDL, HDL subclasses, lipoprotein(a), lipoprotein(b), C-reactive protein, high sensitivity CRP, insulin, insulin resistance, fibrinogen, genetic testing, and homocysteine.
Experimental/Investigational · 2025 · IMR EI25-44331
Findings: The physician reviewer found that the patient requested reimbursement for Apolipoprotein testing. The American College of Cardiology (ACC) as well as the American Heart Association (AHA) guidelines currently do not recommend routine performance of specialized tests in the context of assessing coronary risk including lipoprotein-associated phosholipase A2 (Lp-PLA2), sub-classifications of LDL, HDL subclasses, lipoprotein(a), lipoprotein(b), C-reactive protein, high sensitivity CRP, insulin, insulin resistance, fibrinogen, genetic testing, and homocysteine. Treatment change or addition based on the results of screening with these specialized tests has not been shown to improve cardiac outcomes incremental to that achievable by treatment based on standard risk factor profiling and basic lipid analysis.
Experimental/Investigational · 2024 · IMR EI24-43192

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Cholesterol Screen, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Denied Cholesterol Screen? Use the California record to prepare.

Explain my denial — freeStart my appeal · $9